The Association Between APOE Genotype, Race, and Dementia: An Analysis of 7 Population-Based Cohort Studies
- Journal
- Neurology. Genetics (Q1)
- Published
- 16 July 2026
- Study design
- Prospective / inception cohort
- Evidence level
- Level 2, Moderate (CEBM 2b)
- Authors
- Natalia Lakomski, Katherine Giorgio, John Stephen, Maxwell Mansolf, Aïcha Soumaré, Alden L Gross, et al.
- PMID
- 42519715
- DOI
- 10.1212/NXG.0000000000200417
Why clinicians should know about it
- Picked for Genetics (clinical) (top studies of the week, 2 August 2026).
Abstract
BACKGROUND AND OBJECTIVES: The apolipoprotein E (APOE) haplotypes are known to be associated with dementia, with the ε4 haplotype associated with higher risk. It has been suggested that the APOE ε2 allele serves as a protective factor for dementia. However, data on the effects of the homozygous APOE ε2/ε2 genotype are limited, likely due to the rarity of the APOE ε2/ε2 genotype. Furthermore, the association between APOE genotypes and dementia may differ across self-reported race. We aim to investigate the association between APOE genotypes and dementia overall and across self-reported race, with a focus on the potential protective effects of the ε2 haplotype and differences across race. METHODS: Data from 7 large, community-based, prospective cohort studies from the Dementia Risk Prediction Pooling Project: Age, Gene/Environment Susceptibility-Reykjavik Study, Whitehall II study, Atherosclerosis Risk in Communities Study, Cardiovascular Health Study, Honolulu-Asia Aging Study, Multi-Ethnic Study of Atherosclerosis, and Framingham Heart Study and its associated cohorts were used. Cox proportional hazard models were used to estimate the cause-specific hazard ratios of dementia by APOE genotypes overall and by self-reported race. RESULTS: The study consisted of 45,022 participants (10% Asian, 15% Black, 75% White, 52% male) with a mean age of 56 years (SD: 14.5) at baseline. Compared with participants with an APOE ε3/ε3 genotype, those with an ε2/ε3 genotype had a lower risk of dementia (HR: 0.87, 95% CI 0.80-0.96). There was an indication of protective effects of the ε2/ε2 genotype compared with the ε3/ε3 genotype (HR: 0.98, 95% CI 0.71-1.37). These associations were similar among Black and White participants. The detrimental effect of an ε4/ε4 genotype compared with an ε3/ε3 genotype was also seen overall and among Black and White participants. Those with an APOE ε4/ε4 genotype experienced dementia onset approximately 8 years earlier than those with an APOE ε3/ε3 genotype. DISCUSSION: In this large, pooled cohort, the presence of at least one APOE ε2 allele was associated with lower risk of dementia overall and by self-reported race, suggesting a protective effect. APOE ε4/ε4 was associated with an earlier age of dementia onset with differences across race.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.